Ocuphire Pharma Results

Panorama Study Further Emphasizes Need for Proactive Treatment of NPDR Eyes Treated with Aflibercept Showed a >2-step Improvement in DRSS Level at 24 and 52 Weeks Population: Adults with severe NPDR w/o DME 225 Male; 177 Female Mean Age: 56 years (10.5) Setting: Global, Multi-Center Study Intervention: 402 Eyes randomized to 3 arms (1 eye per participant) ● IVT Aflibercept 2q16 Ocuphire PHARMA ● 2 mg monthly x 3 doses then every 8 weeks x 1 dose, followed by every 16 weeks through week 100 IVT Aflibercept 2q8 as needed 2 mg monthly x 5 doses then every 8 weeks through week 52 then as needed through week 100 Observation with sham IV injections Primary Endpoint: IVT Sham Proportion of participants with ≥2 step improvement in the DRSS scale at 24 and 52 weeks Proportion of Eyes Proportion of Eyes With ≥ 2-Step Improvement in DRSS Score From Baseline Through Week 100 (n = 133) 100% 80% 60% 40% 20% 0% 6% Sham n = 133 15% 13% 24 52 10 0 Aflibercept 2q16 n = 135 61% 65% 62% 24 52 10 Weeks 0 Aflibercept 2q8/PRN n = 134 55% 80% 50% 24 52 10 0 Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. PMID: 34351414; PMCID: PMC8343518. 22

View entire presentation